WallStreetZenWallStreetZen

NASDAQ: GNLX
Genelux Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GNLX

Based on 2 analysts offering 12 month price targets for Genelux Corp.
Min Forecast
$30.00+769.57%
Avg Forecast
$31.00+798.55%
Max Forecast
$32.00+827.54%

Should I buy or sell GNLX stock?

Based on 2 analysts offering ratings for Genelux Corp.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GNLX stock forecasts and price targets.

GNLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-03
lockedlocked$00.00+00.00%2024-04-02

1 of 1

Forecast return on equity

Is GNLX forecast to generate an efficient return?

Forecast return on assets

Is GNLX forecast to generate an efficient return on assets?

GNLX revenue forecast

What is GNLX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$41.2M+24,135.29%
Avg 2 year Forecast
$102.9M+60,429.41%
Avg 3 year Forecast
$196.3M+115,370.59%
GNLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GNLX revenue growth forecast

How is GNLX forecast to perform vs Biotechnology companies and vs the US market?
Company
939.62%
Industry
37.5%
Market
10.08%
GNLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GNLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GNLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GNLX$3.45$31.00+798.55%Buy
DMAC$2.45$7.00+185.71%Buy
ELTX$9.25$11.00+18.92%Buy
BYSI$2.43N/AN/A
ARMP$2.50$7.00+180.00%Buy
View Top Biotech Stocks

Genelux Stock Forecast FAQ

Is Genelux Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GNLX) stock is to Buy GNLX stock.

Out of 2 analysts, 0 (0%) are recommending GNLX as a Strong Buy, 2 (100%) are recommending GNLX as a Buy, 0 (0%) are recommending GNLX as a Hold, 0 (0%) are recommending GNLX as a Sell, and 0 (0%) are recommending GNLX as a Strong Sell.

If you're new to stock investing, here's how to buy Genelux stock.

What is GNLX's revenue growth forecast for 2026-2028?

(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of 939.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Genelux's revenue in 2024 is $170,000.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $1,106,857,488, with the lowest GNLX revenue forecast at $1,106,857,488, and the highest GNLX revenue forecast at $1,106,857,488. On average, 1 Wall Street analysts forecast GNLX's revenue for 2027 to be $2,764,457,172, with the lowest GNLX revenue forecast at $2,764,457,172, and the highest GNLX revenue forecast at $2,764,457,172.

In 2028, GNLX is forecast to generate $5,273,692,350 in revenue, with the lowest revenue forecast at $5,273,692,350 and the highest revenue forecast at $5,273,692,350.

What is GNLX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: GNLX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GNLX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GNLX price target, the average GNLX price target is $31.00, with the highest GNLX stock price forecast at $32.00 and the lowest GNLX stock price forecast at $30.00.

On average, Wall Street analysts predict that Genelux's share price could reach $31.00 by Apr 3, 2025. The average Genelux stock price prediction forecasts a potential upside of 798.55% from the current GNLX share price of $3.45.

What is GNLX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: GNLX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.